Truist Securities Reiterates Buy on Boston Scientific, Maintains $61 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reiterated a 'Buy' rating on Boston Scientific (NYSE:BSX) and maintained a price target of $61.
September 21, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's stock rating has been reiterated as 'Buy' by Truist Securities with a maintained price target of $61.
The reiteration of a 'Buy' rating by a reputable analyst like Richard Newitter from Truist Securities is a positive signal for Boston Scientific. The maintained price target of $61 also indicates confidence in the company's performance, which could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100